Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Nitisinone
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Dipharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Orfadin (nitisinone) is a hydroxy-phenylpyruvate dioxygenase inhibitor indicated for the treatment of adult and pediatric patients with hereditary tyrosinemia type 1.
Product Name : Orfadin-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 31, 2023
Lead Product(s) : Nitisinone
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Dipharma
Deal Size : Inapplicable
Deal Type : Inapplicable